L-Alaninol → 1-ethyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(1S)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide
Reaction equation
[CH2:1]([N:3]1[C:12]2[C:7](=[N:8][CH:9]=[C:10]([CH2:13][C:14]3[CH:19]=[CH:18][C:17]([F:20])=[CH:16][CH:15]=3)[CH:11]=2)[C:6]([OH:21])=[C:5]([C:22](OCC)=[O:23])[C:4]1=[O:27])[CH3:2].[NH2:28][C@@H:29]([CH3:32])[CH2:30][OH:31]>>[CH2:1]([N:3]1[C:12]2[C:7](=[N:8][CH:9]=[C:10]([CH2:13][C:14]3[CH:19]=[CH:18][C:17]([F:20])=[CH:16][CH:15]=3)[CH:11]=2)[C:6]([OH:21])=[C:5]([C:22]([NH:28][C@@H:29]([CH3:32])[CH2:30][OH:31])=[O:23])[C:4]1=[O:27])[CH3:2]Participants
3
Procedure
In a similar manner to that described in example 196, from ethyl 1-ethyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate (60 mg, 0.162 mmol) and (2S)-2-amino-1-propanol (0.05 mL) was prepared 1-ethyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(1S)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide (33 mg, 51% yield) as a white solid after purification by reverse phase HPLC. 1H NMR (CDCl3) δ 10.27 (d, J=7.6 Hz, 1 H), 8.50 (s, 1 H), 7.33 (s, 1 H), 7.16-7.12 (m, 2 H), 7.04-6.98 (m, 2 H), 4.27 (m, 6 H), 3.78 (dd, J=11.2, 3.6 Hz, 1 H), 3.65 (dd, J=11.2, 6 Hz, 1 H), 1.29 (d, J=6.8 Hz, 3 H), 1.19 (m, 3 H); MS m/z 400 (M+1).
Sources & evidence
- ORD record
- ord-1c1d3890798d4fa1a12a4fd6a37ca137
- Source dataset
- uspto-grants-2014_04
- Patent number
- US08691991B2
Reaction notes
Loading…